These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26663867)

  • 1. Use of nanoparticles to deliver immunomodulatory oligonucleotides.
    Klinman DM; Sato T; Shimosato T
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Jul; 8(4):631-7. PubMed ID: 26663867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic utility of stimulatory and suppressive oligodeoxynucleotides.
    Ishii KJ; Gursel I; Gursel M; Klinman DM
    Curr Opin Mol Ther; 2004 Apr; 6(2):166-74. PubMed ID: 15195929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
    Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
    Front Immunol; 2018; 9():783. PubMed ID: 29720976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of CpG oligodeoxynucleotides as immunoprotective agents.
    Klinman DM
    Expert Opin Biol Ther; 2004 Jun; 4(6):937-46. PubMed ID: 15174975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides.
    Leifer CA; Verthelyi D; Klinman DM
    J Immunother; 2003; 26(4):313-9. PubMed ID: 12843793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant activity of CpG oligodeoxynucleotides.
    Klinman DM
    Int Rev Immunol; 2006; 25(3-4):135-54. PubMed ID: 16818369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hierarchical recognition of CpG motifs expressed by immunostimulatory oligodeoxynucleotides.
    Klinman DM; Currie D
    Clin Exp Immunol; 2003 Aug; 133(2):227-32. PubMed ID: 12869028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self-assembly of poly-adenine-tailed CpG oligonucleotide-gold nanoparticle nanoconjugates with immunostimulatory activity.
    Chen N; Wei M; Sun Y; Li F; Pei H; Li X; Su S; He Y; Wang L; Shi J; Fan C; Huang Q
    Small; 2014 Jan; 10(2):368-75. PubMed ID: 23963797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the development of immunostimulatory oligonucleotides.
    Uhlmann E; Vollmer J
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-Assembled DNA Immunonanoflowers as Multivalent CpG Nanoagents.
    Zhang L; Zhu G; Mei L; Wu C; Qiu L; Cui C; Liu Y; Teng IT; Tan W
    ACS Appl Mater Interfaces; 2015 Nov; 7(43):24069-74. PubMed ID: 26440045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.
    Klinman DM; Zeuner R; Yamada H; Gursel M; Currie D; Gursel I
    Ann N Y Acad Sci; 2003 Dec; 1002():112-23. PubMed ID: 14751829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in immunostimulatory CpG oligonucleotides.
    Rothenfusser S; Tuma E; Wagner M; Endres S; Hartmann G
    Curr Opin Mol Ther; 2003 Apr; 5(2):98-106. PubMed ID: 12772497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis.
    Zeuner RA; Verthelyi D; Gursel M; Ishii KJ; Klinman DM
    Arthritis Rheum; 2003 Jun; 48(6):1701-7. PubMed ID: 12794839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides.
    Kamstrup S; Verthelyi D; Klinman DM
    Vet Microbiol; 2001 Feb; 78(4):353-62. PubMed ID: 11182501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanomedicine approaches to improve cancer immunotherapy.
    Qiu H; Min Y; Rodgers Z; Zhang L; Wang AZ
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2017 Sep; 9(5):. PubMed ID: 28296286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthetic methylated CpG ODNs are potent in vivo adjuvants when delivered in liposomal nanoparticles.
    Chikh G; de Jong SD; Sekirov L; Raney SG; Kazem M; Wilson KD; Cullis PR; Dutz JP; Tam YK
    Int Immunol; 2009 Jul; 21(7):757-67. PubMed ID: 19502586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Toll-like Receptor 9 Responses through Synthetic Immunostimulatory Motifs of DNA.
    Agrawal S; Kandimalla ER
    Ann N Y Acad Sci; 2003 Dec; 1002():30-42. PubMed ID: 14751820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular-targeted nanocarriers: design considerations and strategies for successful treatment of atherosclerosis and other vascular diseases.
    Kelley WJ; Safari H; Lopez-Cazares G; Eniola-Adefeso O
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2016 Nov; 8(6):909-926. PubMed ID: 27194461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.